Biopharmaceutical developers are expanding late-stage clinical programs to evaluate metabolic therapeutics across broader cardiovascular and renal endpoints.
Reimbursement Expansion
Health insurers and government payors are revising coverage guidelines as longitudinal outcomes data demonstrates measurable reductions in secondary acute hospitalization events.